Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Tenaya Therapeutics's TN-201?
TN-201 is a gene therapy commercialized by Tenaya Therapeutics, with a leading Phase II program in Hypertrophic Cardiomyopathy. According to...
TN-201 by Tenaya Therapeutics for Hypertrophic Cardiomyopathy: Likelihood of Approval
TN-201 is under clinical development by Tenaya Therapeutics and currently in Phase I for Hypertrophic Cardiomyopathy. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Tenaya Therapeutics's TN-201?
TN-201 is a gene therapy commercialized by Tenaya Therapeutics, with a leading Phase I program in Hypertrophic Cardiomyopathy. According to...